A Phase 1, Randomized, Double-Blind, Single-Dose and Repeat Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Latest Information Update: 20 Nov 2023
At a glance
- Drugs CD 388 (Primary) ; CD 388 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors Cidara Therapeutics
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2023 According to a Cidara Therapeutics media release, data from this study will be presented at IDWeek 2023
- 06 Sep 2023 According to a Cidara Therapeutics, following promising interim efficacy and safety data from ongoing Phase 1 and 2a trials, the Janssen Pharmaceutical, has delivered to Cidara its Election to Proceed Notice for CD388 which is being developed for the universal prevention of influenza A and B. Responsibility for future development, manufacturing and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement.